MX2018013517A - Anticuerpos anti-il-1r3 humanizados. - Google Patents

Anticuerpos anti-il-1r3 humanizados.

Info

Publication number
MX2018013517A
MX2018013517A MX2018013517A MX2018013517A MX2018013517A MX 2018013517 A MX2018013517 A MX 2018013517A MX 2018013517 A MX2018013517 A MX 2018013517A MX 2018013517 A MX2018013517 A MX 2018013517A MX 2018013517 A MX2018013517 A MX 2018013517A
Authority
MX
Mexico
Prior art keywords
antibodies
antibody
cancer
pharmaceutical composition
mediated disease
Prior art date
Application number
MX2018013517A
Other languages
English (en)
Inventor
Brandt Michael
Fischer Stephan
Original Assignee
Mab Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mab Discovery Gmbh filed Critical Mab Discovery Gmbh
Publication of MX2018013517A publication Critical patent/MX2018013517A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La invención actual se refiere a anticuerpos humanizados que se enlazan específicamente a IL-1R3 o un fragmento o derivado del mismo o un polipéptido que contiene al menos una porción de dicho anticuerpo que es suficiente para conferir especificidad de enlace IL-1R3. Dichos anticuerpos inhiben la actividad NFkB inducida por IL-1R3. También inhiben la actividad NFkB estimulada por IL-1alfa, IL-1beta, IL-33, e/o IL-36. La descripción se refiere además al uso de dicho anticuerpo humanizado en el tratamiento de una enfermedad mediada por IL-1R3 tal como cáncer. La descripción abarca finalmente una composición farmacéutica que comprende un portador farmacéuticamente aceptable y una cantidad terapéuticamente efectiva del anticuerpo de acuerdo con la invención. La composición farmacéutica puede usarse en el tratamiento de una enfermedad mediada por IL-1R3 tal como cáncer.
MX2018013517A 2016-05-06 2017-05-08 Anticuerpos anti-il-1r3 humanizados. MX2018013517A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16168617.5A EP3241845A1 (en) 2016-05-06 2016-05-06 Humanized anti-il-1r3 antibodies
PCT/EP2017/060925 WO2017191325A1 (en) 2016-05-06 2017-05-08 Humanized anti-il-1r3 antibodies

Publications (1)

Publication Number Publication Date
MX2018013517A true MX2018013517A (es) 2019-07-08

Family

ID=55919721

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013517A MX2018013517A (es) 2016-05-06 2017-05-08 Anticuerpos anti-il-1r3 humanizados.
MX2023002554A MX2023002554A (es) 2016-05-06 2018-11-05 Anticuerpos anti-il-1r3 humanizados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023002554A MX2023002554A (es) 2016-05-06 2018-11-05 Anticuerpos anti-il-1r3 humanizados.

Country Status (15)

Country Link
US (2) US11203642B2 (es)
EP (2) EP3241845A1 (es)
JP (2) JP7038462B2 (es)
KR (3) KR20230107695A (es)
CN (3) CN116178548A (es)
AU (1) AU2017260399B2 (es)
BR (1) BR112018072681A8 (es)
CA (1) CA3022657A1 (es)
EA (1) EA201892541A1 (es)
IL (2) IL297527A (es)
MX (2) MX2018013517A (es)
NZ (1) NZ748130A (es)
SG (1) SG11201809764XA (es)
WO (1) WO2017191325A1 (es)
ZA (1) ZA201807167B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352432B2 (en) 2017-03-09 2022-06-07 Mab Discovery Gmbh Antibodies specifically binding to human IL-1R7
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
US11248054B2 (en) 2017-06-12 2022-02-15 Bluefin Biomedicine, Inc. Anti-IL1RAP antibodies and antibody drug conjugates
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
KR20230086690A (ko) 2020-09-14 2023-06-15 아이크노스 사이언스 에스. 아. Il1rap에 결합하는 항체 및 이의 용도
WO2022170008A2 (en) * 2021-02-05 2022-08-11 Boehringer Ingelheim International Gmbh Anti-il1rap antibodies
CA3220913A1 (en) 2021-05-21 2022-11-24 Leo Pharma A/S Anti il-1 receptor accessory protein antibodies
WO2024062074A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5283179A (en) 1990-09-10 1994-02-01 Promega Corporation Luciferase assay method
ZA919299B (en) 1990-11-26 1992-08-26 Akzo Nv Method for the production of antibodies
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US6280955B1 (en) 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
WO2002064630A2 (en) 2000-10-31 2002-08-22 Immunex Corporation Il-1 receptor accessory protein
AU2002324625B2 (en) 2001-08-07 2008-05-08 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
DK2213685T3 (en) 2002-09-06 2014-03-03 Medarex Llc Therapeutic anti-IL-1R1 monoclonal antibody
NZ541503A (en) 2003-01-22 2008-09-26 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2005035727A2 (en) 2003-10-09 2005-04-21 Ambrx, Inc. Polymer derivatives
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
US20090215895A1 (en) * 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US8945857B2 (en) 2005-07-01 2015-02-03 John Schrader Methods of isolating cells and generating monoclonal antibodies
CN101291954B (zh) 2005-08-26 2013-03-27 罗氏格黎卡特股份公司 具有改变的细胞信号传导活性的修饰的抗原结合分子
MX2008014692A (es) 2006-05-19 2009-08-18 Alder Biopharmaceuticals Inc Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno.
US8709715B2 (en) 2008-03-26 2014-04-29 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
ES2572728T3 (es) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
EP2400298B1 (en) 2010-05-28 2013-08-14 F.Hoffmann-La Roche Ag Single B-cell cultivation method and specific antibody production
US9403906B2 (en) * 2011-01-19 2016-08-02 Cantargia Ab Method of treatment of a solid tumor with interleukin-1 accessory protein antibody
JP2014519480A (ja) 2011-04-15 2014-08-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌で使用される抗ｉｌ−１ｒ１阻害物質
MX2013013627A (es) * 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
WO2013023015A2 (en) 2011-08-11 2013-02-14 Albert Einstein College Of Medicine Of Yeshiva University Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
WO2014100772A1 (en) 2012-12-21 2014-06-26 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
US10126304B2 (en) 2013-01-16 2018-11-13 George Mason Research Foundation, Inc. Binding domain mapping
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
CN108026172B (zh) 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions

Also Published As

Publication number Publication date
KR20230107695A (ko) 2023-07-17
IL262776B (en) 2022-11-01
JP2019516787A (ja) 2019-06-20
KR102550643B1 (ko) 2023-07-03
WO2017191325A9 (en) 2018-01-04
NZ748130A (en) 2022-08-26
JP7480199B2 (ja) 2024-05-09
EA201892541A1 (ru) 2019-03-29
AU2017260399B2 (en) 2024-03-14
BR112018072681A8 (pt) 2022-06-28
EP3452513B1 (en) 2024-04-17
BR112018072681A2 (pt) 2019-02-19
ZA201807167B (en) 2019-06-26
IL262776B2 (en) 2023-03-01
EP3452513A1 (en) 2019-03-13
US20190194336A1 (en) 2019-06-27
JP2022078191A (ja) 2022-05-24
CN116178549A (zh) 2023-05-30
JP7038462B2 (ja) 2022-03-18
CN116178548A (zh) 2023-05-30
WO2017191325A1 (en) 2017-11-09
EP3241845A1 (en) 2017-11-08
CA3022657A1 (en) 2017-11-09
CN109415442B (zh) 2022-12-23
SG11201809764XA (en) 2018-12-28
IL262776A (en) 2018-12-31
KR20190004762A (ko) 2019-01-14
MX2023002554A (es) 2023-04-10
AU2017260399A1 (en) 2018-11-29
CN109415442A (zh) 2019-03-01
US11203642B2 (en) 2021-12-21
KR102381257B1 (ko) 2022-04-04
US20220089751A1 (en) 2022-03-24
KR20220042499A (ko) 2022-04-05
IL297527A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MY196224A (en) Human Antibodies To Ebola Virus Glycoprotein
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
MX360671B (es) Composición farmacéutica para el tratamiento y/o prevención del cáncer.
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
MX2018010672A (es) Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
BR112016023011A2 (pt) tratamento de câncer gástrico
AU2017260684B2 (en) HER-2 binding antibodies
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof
ZA202205813B (en) Trpv1 epitopes and antibodies
BR112022001037A2 (pt) Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5
MX2022003762A (es) Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma.
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.
MX2021012406A (es) Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1.
EA202092481A1 (ru) Комбинированный способ лечения антагонистом cd73 и антагонистом оси pd-1/pd-l1
MX2020002813A (es) Uso de anticuerpos de union a il-1b para el tratamiento de la hepatitis alcoholica.
EA202092640A1 (ru) Способы и композиции для лечения хронической крапивницы
EA201892069A1 (ru) Способы лечения или профилактики болезни "трансплантат против хозяина"